Interrupted Crosstalk between Natural Killer Cells and Anti-epidermal Growth Factor Receptor: A Possible Role in Hepatocellular Carcinoma Treatment Failure

Author(s): Hadeer Abosalem, Shahenda Mahgoub*, Mohamed Emara, Nahla Kotb, Sameh Soror

Journal Name: Current Cancer Drug Targets

Volume 21 , Issue 7 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hepatocellular carcinoma (HCC) is a major health problem worldwide. Most patients are diagnosed for the first time at late stages, which leads to very poor prognosis. It is challenging to discover strategies for treatment at these advanced stages. Recently, monoclonal antibodies (mAbs) targeting specific cellular signaling pathways in HCC have been developed. Unfortunately, they still have a low survival rate, and some of them failed clinically to produce effective responses even if they showed very good results against HCC in preclinical studies. This review focuses on and discusses the possible causes for the failure of mAbs, precisely anti-Epidermal Growth Factor Receptor (EGFR) mAb and the crosstalk between this mAb and patients' NK cells.

Keywords: HCC immunotherapy, molecular target therapy, tumor microenvironment, NK, anti-EGFR mAb, ADCC.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 18 May, 2021
Page: [601 - 607]
Pages: 7
DOI: 10.2174/1568009621666210519105203
Price: $65

Article Metrics

PDF: 175